EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR TKI that effectively targets EGFR-mutated tumors, including EGFR T790M-positive tumors, has been recommended as an effective treatment for patients with EGFR-mutated NSCLC.